Tshuaj tua kab mob Zevtera (Ceftobiprole medocaril) pom zoo los ntawm FDA rau kev kho mob ntawm CABP, ABSSSI thiab SAB 

Qhov dav-spectrum thib tsib tiam cephalosporin tshuaj tua kab mob, Zevtera (Ceftobiprole medocaril sodium Inj.) tau pom zoo los ntawm FDA¹ rau lub kev kho mob ntawm peb kab mob viz.  

1. Cov kab mob Staphylococcus aureus (bacteremia) (SAB), suav nrog cov neeg uas muaj kab mob endocarditis sab xis;  

2. mob kab mob ntawm daim tawv nqaij thiab kab mob ntawm daim tawv nqaij (ABSSSI); thiab  

3. community-acquired bacterial pneumonia (CABP).  

Qhov no ua raws li qhov txaus siab rau theem 3 kev sim tshuaj ntsuam xyuas.  

Ceftobiprole medocaril tau pom zoo nyob hauv ntau lub tebchaws nyob sab Europe, nrog rau Canada rau kev kho mob ntsws ntsws hauv tsev kho mob (tsis suav nrog lub tshuab ua pa-tau txais mob ntsws) thiab mob ntsws hauv zej zog hauv cov neeg laus.².  

Hauv tebchaws Askiv, Ceftobiprole medocaril yog tam sim no nyob rau theem III kev kuaj mob³ Txawm li cas los xij, nws raug lees txais rau kev txwv tsis pub siv hauv NHS Scotland⁴.  

Hauv EU, nws tshwm nyob rau hauv Union Register ntawm tsis kam kho cov khoom siv rau tib neeg⁵. 

Ceftobiprole medocaril, thib tsib tiam dav-pom cephalosporin zoo tiv thaiv kab mob Gram-zoo xws li methicillin-resistant Staphylococcus aureus thiab penicillin-resistant Streptococcus pneumoniae, thiab tiv thaiv kab mob Gram-negative xws li Pseudomonas aeruginosa. Nws tau pom muaj txiaj ntsig zoo hauv kev kho cov mob ntsws hauv zej zog thiab nosocomial pneumonia, tshwj tsis yog rau lub tshuab ua pa uas cuam tshuam nrog mob ntsws.^6,7. 

*** 

References:  

1. FDA Xov xwm tawm. FDA Pom Zoo Tshiab Tshuaj tua kab mob rau peb qhov sib txawv siv. Tshaj tawm 03 Plaub Hlis 2024. Muaj nyob ntawm https://www.fda.gov/news-events/press-announcements/fda-approves-new-antibiotic-three-different-uses/ 

2. Jame W., Basgut B., thiab Abdi A., 2024. Ceftobiprole mono-therapy piv rau kev sib xyaw ua ke lossis tsis sib xyaw ua ke ntawm tus qauv tshuaj tua kab mob rau kev kho mob ntawm cov kab mob nyuaj: Kev tshuaj xyuas thiab kev tshuaj xyuas meta. Kev kuaj mob Microbiology thiab Kab Mob Sib Kis. Muaj nyob online 16 March 2024, 116263. DOI: https://doi.org/10.1016/j.diagmicrobio.2024.116263  

3. NIHR. Health Technology Briefing Kaum Ib Hlis 2022. Ceftobiprole medocaril rau kev kho mob ntsws hauv tsev kho mob lossis mob ntsws hauv zej zog uas yuav tsum tau mus pw hauv tsev kho mob hauv cov menyuam yaus. Muaj nyob ntawm https://www.io.nihr.ac.uk/wp-content/uploads/2023/04/28893-Ceftobiprole-medocaril-for-pneumonia-V1.0-NOV2022-NONCONF.pdf  

4. Scottish Medicine Consortium. Ceftobiprole medocaril (Zevtera). Muaj nyob ntawm https://www.scottishmedicines.org.uk/medicines-advice/ceftobiprole-medocaril-zevtera-resubmission-94314/  

5. European Commission. Union Register ntawm tsis kam tshuaj cov khoom rau tib neeg siv. Hloov tshiab kawg ntawm 21 Lub Ob Hlis 2024. Muaj nyob ntawm https://ec.europa.eu/health/documents/community-register/html/ho10801.htm 

6. Lupia T. thiab al 2022. Ceftobiprole Perspective: Tam sim no thiab muaj peev xwm yav tom ntej Indications. Tshuaj tua kab mob Volume 10 Issue 2. DOI: https://doi.org/10.3390/antibiotics10020170  

7. Méndez1 R., Latorre A., and González-Jiménez P., 2022. Ceftobiprole medocaril. Rev Esp Quimioter. 2022; 35 (Ntawv qhia zaub mov 1): 25–27. Luam tawm online 2022 Plaub Hlis 22. DOI: https://doi.org/10.37201/req/s01.05.2022  

***